Systemic sclerosis: Environmental factors

Journal of Rheumatology

Volumn 36, Issue 11, 2009, Pages 2383-2396

  Mora, Gabriela Fernanda ^a,b  

^a Grupo de Estudio   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Environmental Exposure; Epidemiology; Risk Factors; Systemic sclerosis

Indexed keywords

5 HYDROXYTRYPTOPHAN; ALIPHATIC HYDROCARBON; AMFEPRAMONE; AROMATIC HYDROCARBON; BIOLOGICAL MARKER; BLEOMYCIN; CARBIDOPA; COCAINE; DEXAMPHETAMINE; FENFLURAMINE; FENPROPOREX; GADOLINIUM; INORGANIC COMPOUND; MAZINDOL; METHAQUALONE; ORGANIC SOLVENT; PENTAZOCINE; PESTICIDE; PHENMETRAZINE; SILICON DIOXIDE; SILICONE; VINYL CHLORIDE;

BACTERIAL INFECTION; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; GENE INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; OCCUPATIONAL HAZARD; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC SCLEROSIS; VIRUS INFECTION;

ENVIRONMENTAL EXPOSURE; HUMANS; IMMUNE SYSTEM; MOLECULAR MIMICRY; OCCUPATIONAL EXPOSURE; RISK FACTORS; SCLERODERMA, SYSTEMIC; SILICON DIOXIDE; SOLVENTS;

EID: 70450173918     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090207     Document Type: Review

References (154)

1. Erasmus LD. Scleroderma in gold miners on the Witwatersrand with particular reference to pulmonary manifestations. S Afr J Lab Clin Med 1957;3:209-231
2. Gunther G, Shuchardt E. Silicosis and progressive scleroderma. Is there an etiologic connection? [in German] Dtsch Med Wochenschr 1970;95:467-468
3. Sluis-Cremer GK, Hessel PA, Nizdo EH, Churchill AR, Zeiss EA. Silica-silicosis, and progressive systemic sclerosis. Br J Ind Med 1985;41:838-843
4. Haustein UF, Ziegler MD. Environmentally induced systemic sclerosis-like disorders. Int J Dermatol 1985;24:147-151
5. Sanchez-Roman J, Wichmann I, Salaberri J, Varela JM, Nunez-Roldan A. Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica. Ann Rheum Dis 1993;52:534-538 (Pubitemid 23227220)
6. Owens GR, Medsger TA. Systemic sclerosis secondary to occupational exposure. Am J Med 1988;85:114-116
7. Rodnan GP, Benedek TG, Medsger TA, Cammarata RJ. The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis. Ann Intern Med 1967;66:323-334
8. Harris DK, Adams WGF. Acroosteolysis occurring in men engaged in the polymerisation of vinyl chloride. BMJ 1967;3:712-714
9. Lange CE, Juhe S, Veltman G. The occurrence of liver angiosarcoma in 2 patients in the PVC manufacturing industry. Dtsch Med Wochenschr 1974;99:1598-1599
10. Ward AM, Udnoon S, Watkins J, Walker AE, Darke CS. Immunological mechanisms in the pathogenesis of vinyl chloride disease. BMJ 1976;1:936-938
11. Kissel P, Schmitt J, Barrucand D, Sapelier J. Reports of scleroderma and silicosis: an observation. Ann Med Nancy 1965;4:26-34.
12. Cauvet M, Matrin E. Silicose and sclerodermis. Schweiz Med Wochenschr Suppl 1969;4:1261-1263
13. Englert H, Small-McMahon J, Davis K, O'Connor H, Chambers P, Brooks P. Male systemic sclerosis and occupational silica exposure - a population-based study. Aust NZ J Med 2000;30:215-220 (Pubitemid 30304475)
14. Walder B. Solvents and scleroderma. Lancet 1965;ii:436-437
15. Brasington RD, Thorpe-Swenson AJ. Systemic sclerosis associated with cutaneous exposure to solvent: case report and review of the literature. Arthritis Rheum 1991;34:631-633
16. Yamakage A, Ishikawa H, Saito Y, Hattori A. Occupational scleroderma-like disorder occurring in men engaged in the polymerisation of epoxy resins. Dermatologica 1980;161:44. (Pubitemid 10156816)
17. Diaz de R, Castro Garcia M, Borda A, Alonso Gordo JM, Posada de la Paz M, Kilbourne EM, et al. The association of oil ingestion with toxic oil syndrome in two convents. Am J Epidemiol 1987;125:907-912 (Pubitemid 17066490)
18. Finch WR, Rodnan GP, Buckingham RB, Prince RK, Winkelstein W. Bleiomycin-induced scleroderma. J Rheumatol 1980;7:651-659
19. Silver RM, Heyes MP, Maize C, Quearry B, Vionnet-Fuasset MD, Sternberg EM. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 1990;322:874-881 (Pubitemid 20108376)
20. Aeschlimann A, de Truchis P, Kahn MF. Scleroderma after therapy with appetite suppressants. Report on four cases. Scand J Rheumatol 1990;19:87-90. (Pubitemid 20062489)
21. Palestine RF, Millns JL, Spigel GT, Schroeter AL. Skin manifestations of pentazocine abuse. Am Acad Dermatol 1980;2:47-55.
22. Rose T, Nothjunge J, Schlote W. Familial occurrence of dermatomyositis and progressive scleroderma after injection of a local anaesthetic for dental treatment. Eur J Pediatr 1985;143:225-228 (Pubitemid 15130710)
23. Skouby AP. Sclerodermia-like picture following a single serum injection. Acta Med Scand 1949;136:51-55
24. Silman AJ, Hicklin AJ, Black C. Geographical clustering of scleroderma in south and west London. Br J Rheumatol 1990;29:92-96 (Pubitemid 20122797)
25. Valesini G, Litta A, Bonavita MS, Luan FL, Purpura M, Mariani M, et al. Geographical clustering of scleroderma in a rural area in the province of Rome. Clin Exp Rheumatol 1993;11:41-47 (Pubitemid 23050851)
26. Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol 2002;29:1867-1873
27. Englert H, Joyner J, Bade R, Thompson M, Morris D, Chambers P, et al. Systemic scleroderma: a spaciotemporal clustering. Intern Med J 2005;35:228-233
28. Gourley M, Miller F. Mechanisms of disease: environmental factors in the pathogenesis of rheumatic disease. Nat Clin Pract Rheumatol 2007;3:171-180 (Pubitemid 46416266)
29. Ueki A, Yamaguchi M, Ueki H, Watanabe Y, Ohsawa G, Kinugawa K, et al. Polyclonal human T-cell activation by silicate in vitro. Immunology 1994;82:332-335 (Pubitemid 24241752)
30. Wang Y, Fan P, Kahaleh B. Association between enhanced type I collagen expressionand epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006;54:2271-2279 (Pubitemid 44051084)
31. Razin A, Cedar H. DNA methylation and gene expression. Microbiol Rev 1991;55:451-458
32. James G, Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054 (Pubitemid 37448928)
33. He H, Lehming N. Global effects of histone modifications. Brief Funct Genomic Proteomic 2003;2:234-243
34. Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009;33:3-11.
35. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am 1994;20:61-86.
36. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988;140:2197-2200 (Pubitemid 18098475)
37. Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 2005;280:40749-40756 (Pubitemid 41780565)
38. Koeger AC, Lang T, Alcaix D, Milleron B, Rozenberg S, Chaibi P, et al. Silica-associated connective tissue disease. A study of 24 cases. Medicine (Baltimore) 1995;74:221-237
39. Khan MF, Kaphalia BS, Prabhakar BS, Kanz MF, Ansari GA. Trichloroethene-induced autoimmune response in female MRL +/+ mice. Toxicol Appl Pharmacol 1995;134:155-160
40. Byers V, Levin A, Ozonoff D, Baldwin R. Association between clinical symptoms and lymphocyte abnormalities in a population with chronic domestic exposure to industrial solvent-contaminated domestic water supply and a high incidence of leukaemia. Cancer Immunol 1988;27:77-81. (Pubitemid 18176249)
41. Bottomley W, Sheehan-Dare R, Hughes P, Cunliffe W. A sclerodermatous syndrome with unusual features following prolonged occupational exposure to organic solvents. Br J Dermatol 1993;128:203-206 (Pubitemid 23054340)
42. Yoshida S, Gershwin M. Autoimmunity and selected environmental factors of disease induction. Semin Arthritis Rheum 1993;22:399-419. (Pubitemid 23178975)
43. Knight K, Gibbons R. Increased collagen synthesis and cross-link formation in the skin of rats exposed to vinyl chloride monomer. Clin Sci (Lond) 1987;72:673-678 (Pubitemid 17077528)
44. Guilherme L, Faé K, Oshiro SE, Kalil J. Molecular pathogenesis of rheumatic fever and rheumatic heart disease. Expert Rev Mol Med 2005;7:1-15.
45. Pleister A, Eckels DD. Cryptic infection and autoimmunity. Autoimmun Rev 2003;2:126-132
46. Maul G, Jimenez S, Riggs E, Ziemnicka-Kotula D. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci USA 1989;86:8492-8496 (Pubitemid 19286081)
47. Muryoi T, Kasturi K, Kafina M, Cram DS, Harrison LC, Sasaki T, et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med 1992;175:1103-1109
48. Rosenman KD, Zhu Z. Pneumnoconiosis and asscociated medical conditions. Am J Ind Med 1995;27:107-113
49. Rosenman KD, Moore-Fuller M, Reilly MJ. Connective tissue disease and silicosis. Am J Ind Med 1999;25:375-381
50. Van Loveren H, Vos JG, Germolec D, Simeonova PP, Eijkemanns G, McMichael AJ. Exploratory Meeting: Epidemiology of occupational and environmental factors associated with autoimmunity. Bilthoven, The Netherlands; 2000.
51. Davis BL, Johnson LR, Stevens RK, Courtney WJ, Safriet DW. The quartz content and elemental composition of aerosols from selected sites of the EPA Inhalable Particulate Network. Atmos Environ 1984;18:771-782 (Pubitemid 16262075)
52. Norboo T, Angchuk PT, Yahya M, Kamat SR, Pooley FD, Corrin B, et al.Silicosis in a Himalayan village population: role of environmental dust. Thorax 1991; 46:341-343.
53. Occupational Safety and Health Administration. OSHA Safety and Health Standards (29 CFR 1910) - General Industry. OSHA Publ no 2206. Washington, DC: U.S. Department of Labor; 1983.
54. Parks C, Conrad K, Cooper G. Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 1999; 107 Suppl:793-802.
55. IARC. Silica. In: IARC monographs on the evaluation of the carcinogenic risk of chemical to humans. Vol 68: Silica and some silicates. Lyon: International Agency for Research on Cancer; 1997.
56. Ziskind M, Jones R, Weill H. Silicosis. Am Rev Resp Dis 1976;713:643-665
57. Bramwell B. Diffuse scleroderma: Its frequency, its occurrence in stone masons, its treatment by fibrinolysin injections, elevations of temperature due to fibrinolysin. Edinb J Med 1914;12:387-401.
58. Caux F, Chosidow O, De Cremoux H, Roujeau JC, Revuz J. Dental prosthesis technician, a subject with risk of Erasmus syndrome. Apropos of a case [French]. Ann Dermatol Venereol 1991;118:301-304
59. Christy W, Rodnan G. Conjugal progressive systemic sclerosis (scleroderma). Report of the disease in husband and wife. Arthritis Rheum 1984;27:251-254
60. Cowie R. Silica dust-exposed mine workers with scleroderma (systemic sclerosis). Chest 1987;92:260-262 (Pubitemid 17125830)
61. Melhorn J, Enderlein G, Conrad K, Ziegler V. Analysis for the association between progressive systemic scleroderma, exposure to quartz dust and silicosis in East German uranium miners. Zentralbl Arbeitsmed 1999;49:134-147 (Pubitemid 29274637)
62. Steenland K, Brown D. Mortality study of gold miners exposed to silica and nonasbestiform amphibole minerals: an update with 14 more years of follow-up. Am J Ind Med 1995;27:217-229
63. Brown LM, Gridley G, Olsen JH, Mellemkjaer L, Linet MS, Fraumeni JF Jr. Cancer risk and mortality patterns among silicotic men in Sweden and Denmark. J Occup Eviron Med 1997;39:633-638 (Pubitemid 27327246)
64. Walsh S. Divergent effects of occupational silica exposure on proportional mortality from systemic sclerosis and silicosis [abstract]. Arthritis Rheum 1997;40 Suppl:S262.
65. Calvert GM, Rice FL, Boiano JM, Sheehy JW, Sanderson WT. Occupational silica exposure and risk of various deseases: an analysis susing death certificates from 27 states of the United States. Occup Environ Med 2003;60:122-129
66. Ziegler V, Enderlein G, Melhorn J, Conrad K. Retrospective epidemiological analysis of the relation between progressive systemic scleroderma and the exposure to quartz dust out of uranium ore mining in East Germany. Zentralbl Arbeitsmed 1997;47:7-13. (Pubitemid 27115721)
67. Haustein U, Anderegg U. Silica induced scleroderma - clinical and experimental aspects. J Rheumatol 1998;25:1917-1926 (Pubitemid 28459304)
68. Magnant J, de Monte M, Guilmot JL, Lasfargues G, Diot P, Asquier E, et al. Relationship between occupational risk factors and severity markers of systemic sclerosis. J Rheumatol 2005;32:1713-1718 (Pubitemid 41324809)
69. Silman A, Jones S. What is the contribution of environmental factors to the occurrence of scleroderma in men? Arthritis Rheum 1992;51:1322-1324
70. Bovenzi M, Barbone F, Betta A, Tommasini M, Versini W. Scleroderma and occupational exposure. Scan J Work Environ Health 1995;21:289-292
71. Burns CJ, Laing TJ, Gillespie BW, Heeringa SG, Alcser KH, Mayes MD, et al. The epidemiology of scleroderma among women: assessment of risk from exposure to silicone and silica. J Rheumatol 1996;23:1904-1911
72. Mora G. Esclerodermia inducida por sílice. Tesis Doctoral. Facultad de Medicina, Universidad de Buenos Aires, Argentina; 2003.
73. Bovenzi M, Barbone F, Pisa FE, Betta A, Romeo L, Tonello A, et al. A case-control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ Health 2004;77:10-16 (Pubitemid 38094416)
74. Wilson RH, McCormick WE, Tatum CF, Creech JL. Occupational acroosteolysis. Report of 31 cases. JAMA 1967;201:577-581
75. Veltman G, Lange CE, Jühe S, Stein G, Bachner U. Clinical manifestations and course of vinyl chloride disease. NY Acad Sci 1975; 246: 6-17.
76. Black CM, Welsh KI, Walker AE, Bernstein RM, Catoggio LJ, McGregor AR, et al. Genetic susceptibility to a scleroderma-like syndrome induced by vinyl chloride. Lancet 1983;1:53-55 (Pubitemid 13211293)
77. Garabrant D, Dumas C. Epidemiology of organic solvents and connective tissue disease. Arthritis Res 2000;2:5-15. (Pubitemid 32223679)
78. Reinl W. Scleroderma caused by trichloroethylene in workers. Bull Hyg 1957;32:678.
79. Kettaneh A, Al Moufti O, Tiev KP, Chayet C, Tolédano C, Fabre B, et al. Occupational exposure to solvents and gender-related risk of systemic sclerosis: a metaanalysis of case-control studies. J Rheumatol 2007;34:97-103. (Pubitemid 46106568)
80. Czirjak L, Kumanovics G. Exposure to solvents in female patients with scleroderma. Clin Rheumatol 2002;21:114-118 (Pubitemid 34649591)
81. Goldman JA. Connective tissue disease in people exposed to organic chemical solvents. Systemic sclerosis (scleroderma) in dry cleaning plants and aircraft industry workers. J Clin Rheumatol 1996;2:185-190
82. Zachariae H, Bjerring P, Sondergaard KH, Halkier-Sorensen L. Arbejdsbetinget systemisk sklerodermi hos maend. Ugeskr Laeger 1997;159:2687-2689
83. Nietert PJ, Sutherland SE, Silver RM, Pandey JP, Knapp RG, Hoel DG, et al. Is occupational organic solvent exposure a risk factor for scleroderma? Arthritis Rheum 1998;41:1111-1118
84. Diot E, Lesire V, Guilmot J, Metzger M, Pilore R, Rogier S, et al. Systemic sclerosis and occupational risk factors: A case-control study. Occup Environ Med 2002;59:545-549 (Pubitemid 34864549)
85. Garabrant DH, Lacey JV Jr, Laing TJ, Gillespie BW, Mayes MD, Cooper BC, et al. Scleroderma and solvent exposure among women. Am J Epidemiol 2003;157:493-500.
86. Maitre A, Hours M, Bonneterre V, Arslan MT, Carpentier P, Bergeret A, et al. Systemic sclerosis and occupational risk factors: Role of solvents and cleaning products. J Rheumatol 2004;31:2395-2401 (Pubitemid 39603087)
87. Fessel W. Scleroderma and welding. N Eng J Med 1977;296:1537.
88. Pelmear PL, Roos J, Maehle W. Occupationally-induced scleroderma. J Occup Med 1992;34:20-25
89. Blair H, Headington J, Lynch P. Occupational trauma, Raynaud phenomenon, and sclerodactylia. Arch Environ Health 1974;28:80-81
90. Bovenzi M, Barbone F, Pisa F, Betta A, Romeo L. Scleroderma and occupational exposure to hand-transmitted vibration. Int Arch Occup Environ Health 2001;74:579-582 (Pubitemid 33089326)
91. Hamamdzic D, Kasman L, LeRoy C. Role of infectious agents in the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2002;14:694-698 (Pubitemid 35191558)
92. Heidt PJ, Vossen JM: Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation. J Med 1992;23:161-173
93. Waer M, Ang KK, Van der Schueren E, Vandeputte M. Allogeneic bone marrow transplantation in mice after total lymphoid irradiation: influence of breeding conditions and strain of recipient mice. J Immunol 1984;132:991-996 (Pubitemid 14189129)
94. Vossen JM, Heidt PJ, van den Berg H, Gerritsen EJ, Hermans J, Dooren LJ. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1990;9:14-23. (Pubitemid 20046730)
95. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71:437-439
96. Gasbarrini A, Massari I, Serricchio M, et al. Helicobacter pylori eradication ameliorates primary Raynaud's phenomenon. Dig Dis Sci 1998;43:1641-1645
97. Csiki Z, Gal I, Sebesi J, Szegedi G. Raynaud syndrome and eradication of Helicobacter pylori. Orv Hetil 2000;141:2827-2829
98. Aragona P, Magazzu G, Macchia G, Bartolone S, Di Pasquale G, Vitali C, et al. Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjogren's syndrome. J Rheumatol 1999;26:1306-1311
99. Savarino V, Sulli A, Zentilin P, Raffaella Mele M, Cutolo M. No evidence of an association between Helicobacter pylori infection and Raynaud phenomenon. Scand J Gastroenterol 2000;35:1251-1254
100. Sulli A, Seriolo B, Savarino V, Cutolo M. Lack of correlation between gastric Helicobacter pylori infection and primary or secondary Raynaud's phenomenon in patients with systemic sclerosis. J Rheumatol 2000;27:1820-1821
101. Danese S, Zoli A. Cremonini F, Gasbarrini A. High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis. J Rheumatol 2000;27:1568-1569
102. Zhou YF, Shou M, Harrell RF, Yu ZX, Unger EF, Epstein SE. Chronic non-vascular cytomegalovirus infection: effects on the neointimal response to experimental vascular injury. Cardiovasc Res 2000;45:1019-1025 (Pubitemid 30089664)
103. Presti RM, Pollock AJ, Dal Canto AK, O'Guin AK, Virgin HW 4th. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med 1998;188:577-588
104. Vaughan JH, Shaw PX, Nguyen MD, Medsger TA Jr, Wright TM, Metcalf JS, et al. Evidence of activation of 2 herpes viruses, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skin. J Rheumatol 2000;27:821-824
105. Neidhart M, Kuchen S, Distler O, Brühlmann P, Michel BA, Gay RE, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 1999;42:389-392 (Pubitemid 29072859)
106. Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, Tamassia N, et al. Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis. A gene array approach. PLoS Med 2006;3:94-108.
107. Hamamdzic D, Harley RA, Hazen-Martin D, LeRoy EC. MCMV induces neointima in IFN-gamma R-/- mice: intimal cell apoptosis and persistent proliferation of myofibroblasts. BMC Musculoskeletal Disord 2001;2:3.
108. Artlett CM, Cox LA, Jimenez SA. Detection of cellular microchimerism of male or female origin in systemic sclerosis patients by polymerase chain reaction analysis of HLA-Cw antigens. Arthritis Rheum 2000;43:1062-1067
109. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998;338:1186-1191 (Pubitemid 28180747)
110. Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998;351:559-562 (Pubitemid 28077562)
111. Waldman WJ. Cytomegalovirus as a perturbing factor in graft/host equilibrium: havoc at the endothelial interface. In: Scholz M, Rabenau HF, Doerr HW, eds. CMV-Related Immunopathology. Monographs in Virology, Vol.21. Basel: Karger; 1998: 54-66.
112. Ferri C, Zakrzewska K, Longombardo G, Giuggioli D, Storino FA, Pasero G, et al. Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol 1999;17:718-720
113. Cobeta-Garcia JC, Rodilla F. Antinucleolar antibodies and Parvovirus B19 arthritis [letter]. Clin Exp Rheumatol 2000;18:537. (Pubitemid 30616958)
114. Altschuler EL. The historical record is consistent with the recent finding of Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol 2001;19:228.
115. de Silva U, Parish LC. Historical approach to scleroderma. Clin Dermatol 1994;12:201-205
116. Beebe J, Lacey J Jr, Mayes M, Gillespie BW, Cooper BC, Laing TJ, et al. Reproductive history, oral contraceptive use, estrogen replacement therapy and the risk of developing scleroderma. Arthritis Rheum 1997;40:S100.
117. Fraenkel L, Zhang Y, Chaisson C, Evans SR, Wilson PW, Felson DT. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 1998;129:208-211 (Pubitemid 28377511)
118. Mayes M. Epidemiologic studies of environmental agents and systemic autoinmune diseases. Environ Health Perspect 1999;107 Suppl:743-748 (Pubitemid 29527779)
119. Silman A, Hochberg M. Occupational and environmental influences in scleroderma. Rheum Dis Clin NA 1996;22:737-749
120. Sternberg EM, van Woert MH, Young S, Magnussen I, Baker H, Gauthier S, et al. Development of a scleroderma-like illness during therapy with L15-Hydroxytryptophan and carbidopa. N Engl J Med 1980;303:782-787 (Pubitemid 10002377)
121. Umezawa H, Maeda K, Takeuchi T, Okami I. New antibiotics, bleomycin A and B. J Antibiot 1966;19:200-209
122. Remlinger KA. Cutaneous reactions to chemotherapy drugs. The art of consultation. Arch Dermatol 2003;139:77-81.
123. Westergren-Thorsson G, Hernnas J, Sarnstrand B, Oldberg A, Heinegård D, Malmström A, et al. Altered expression of small proteoglycans, collagen, and transforming growth factor-b1 in developing bleomycin induced pulmonary fibrosis in rats. J Clin Invest 1993;92:632-637 (Pubitemid 23262379)
124. Raghow R, Lurie S, Seyer J, Kang AH. Profiles steady state levels of messenger RNAs coding for type I procollagen, elastin, and fibronectin in hamster lungs undergoing bleomycin-induced interstitial pulmonary fibrosis. J Clin Invest 1985;76:1733-1739 (Pubitemid 16196039)
125. Clark J C, Starcher B, Uitto J. Bleomycin-induced synthesis of type I procollagen by human lung skin fibroblasts in culture. Biochim Biophys Acta 1980;631:359-370 (Pubitemid 10018159)
126. Yamamoto T, Eckes B, Krieg T. Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin gene expression in human skin fibroblasts. Arch Dermatol Res 2000;292:556-561 (Pubitemid 32003039)
127. Mountz J, Downs Minor M, Turner R, Thomas MB, Richards F, Pisko E. Bleomycin-induced cutaneous toxicity in the rat: analysis of histopathology and ultrastructure compared with progressive systemic sclerosis (scleroderma). Br J Dermatol 1983;108:679-686
128. Kerr L, Spiera H. Scleroderma in association with the use of bleomycin: A report of three cases. J Rheumatol 1992;19:294-296
129. Prchal D, Holmes D, Levin A. Nephrogenic systemic fibrosis: the story unfolds. Kidney Int 2008;73:1135-1137 (Pubitemid 351770488)
130. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1001
131. Leboit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003;139:928-930 (Pubitemid 36898932)
132. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108
133. Information on gadolinium-containing contrast agents. Center for Drug Evaluation and Research, United States Food and Drug Administration. http://www.fda.gov/cder/drug/infopage/gcca/default.htm〉 (2006).
134. Kilaru P, Kim W, Sequeira W. Cocaine and scleroderma: Is there an association? J Rheumatol 1991;8:1753-1755
135. Trozak D, Gould W. Cocaine abuse and connective tissue disease. J Am Acad Dermatol 1984;10:525. (Pubitemid 14150145)
136. Robinson CJ, White H, Rose N. Murine strain differences in response to mercuric chloride: antinucleolar antibody production does not correlate with renal immune complex deposition. Clin Immunol Immunopathol 1997;83:127-138 (Pubitemid 27195932)
137. Hanley G, Schiffenbauer J, Sobel E. Resistance to HgC12-induced autoimmunity in haplotype-heterozygous mice is an intrinsic property of B cells. J Immunol 1998;161:1778-1785 (Pubitemid 28387597)
138. Pollard K, Lee D, Casiano C, Bluthner M, Johnston MM, Tan EM. The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties. J Immunol 1997;158:3521-3528 (Pubitemid 127484074)
139. Arnett F, Reveille J, Goldstein R, Pollard KM, Leaird K, Smith EA. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39:1151-1160
140. Shekhar P, Werdell J, Basrur V. Environmental estrogen stimulation of growth and estrogen receptor function in preneoplastic and cancerous human breast cell lines. J Natl Cancer Inst 1997;89:1774-1782 (Pubitemid 27516231)
141. Bergeron J, Crews D, McLachlan J. PCBs as environmental estrogens: turtle sex determination as a biomarker of environmental contamination. Environ Health Perspect 1994;102:780-781 (Pubitemid 24291038)
142. Tian Y, Ke S, Thomas T, Meeker RJ, Gallo MA. Transcriptional suppression of estrogen receptor gene expression by 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD). J Steroid Biochem Mol Biol 1998;67:17-24.
143. White K Jr, Lysy H, McCay J, Anderson AC. Modulation of serum complement levels following exposure to polychlorinated dibenzo-p-dioxins. Toxicol Appl Pharmacol 1986;84:209-219 (Pubitemid 16090486)
144. Dunnill M, Black M. Sclerodermatous syndrome after occupational exposure to herbicides-response to systemic steroids. Clin Exp Dermatol 1994;19:518-520
145. English J, Rycroft R, Calnan CD. Allergic contact dermatitis from aminotriazole. Contact Derm 1986;14:255-256
146. Laing T, Gillespie B, Burns C, Garabrant D, Heeringa S, Alcser K, et al. Risk factors for scleroderma among Michigan women [abstract]. Arthritis Rheum 1995;38:S341.
147. Levier R, Harrison M, Cook R, Lane TH. What is silicone? J Clin Epidemiol 1995;48:513-517
148. Cook R, Harrison M, Levier R. The breast implant controversy. Arthritis Rheum 1994;37:153-157
149. Miyoshi K, Miyaoka T, Kobayashi Y, Itahura T, Nishijo K, Hagashitara M, et al. Hypergammaglobulinemia by prolonged adjuvanticity in man: Disorders developed after augmentation mammoplasty. Ijishimpo 1964;2122:9-14.
150. Kumagai Y, Shiokawa Y, Medsger T, Rodnan G. Clinical spectrum of connective tissue disease after cosmetic surgery: Observations of eighteen patients and a review of the Japanese literature. Arthritis Rheum 1984;27:1-12. (Pubitemid 14176530)
151. Gabriel S, O'Fallon W, Kurland L, Beard CM, Woods JE, Melton LJ. Risk of connective-tissue diseases and other disorders after breast implantation. N Engl J Med 1994;330:1697-1702 (Pubitemid 24171027)
152. Sanchez-Guerrero J, Colditz G, Karlson E, Hunter D, Speizer F, Liang M. Silicone breast implants and the risk of connective tissue diseases and symptoms. N EngI J Med 1995;332:1666-1670
153. Hochberg M, Perlmutter D, Medsger T Jr, Nguyen K, Steen V, Weisman M, et al. Lack of association between of augmentation mammoplasty and systemic sclerosis. Arthritis Rheum 1996;39:1125-1131 (Pubitemid 26240224)
154. Hennekens C, Lee M, Cook N, Hebert PR, Karlson EW, LaMotte F, et al. Self-reported breast implants and connective tissue diseases in female health Professionals. A retrospective cohort study. JAMA 1996;275:616-621